Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial

BACKGROUND: Over 70% of the patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage and lose the opportunity for radical surgery. Combination therapy of tyrosine kinase inhibitors (TKIs) and anti-programmed cell death protein-1 (PD-1) antibodies has achieved a high tumor resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wenwen, Tong, Shuang, Hu, Bingyang, Wan, Tao, Tang, Haowen, Zhao, Feilong, Jiao, Tianyu, Li, Junfeng, Zhang, Ze, Cai, Jinping, Ye, Huiyi, Wang, Zhanbo, Chen, Shiqing, Wang, Yafei, Li, Xuerui, Wang, Fangzhou, Cao, Junning, Tian, Lantian, Zhao, Xiaochen, Chen, Mingyi, Wang, Hongguang, Cai, Shouwang, Hu, Minggen, Bai, Yuezong, Lu, Shichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514649/
https://www.ncbi.nlm.nih.gov/pubmed/37730273
http://dx.doi.org/10.1136/jitc-2023-007366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514649/
https://www.ncbi.nlm.nih.gov/pubmed/37730273
http://dx.doi.org/10.1136/jitc-2023-007366

Ejemplares similares